Previous 10 | Next 10 |
Janssen Pharmaceutica, a unit of Johnson & Johnson ([[JNJ]] +0.6%) has received two positive opinions from the European Medicines Agency ((EMA)) to broaden the current marketing authorization for DARZALEX (daratumumab) subcutaneous formulation ((SC)).One recommendation is for it...
Halozyme Announces Janssen Receives Two Positive CHMP Opinions for DARZALEX® (daratumumab) Subcutaneous Formulation Utilizing ENHANZE® - For Use of Subcutaneous Daratumumab in Combination with Cyclophosphamide, Bortezomib and Dexamethasone (D-VCd) in Newly Diagnosed Ad...
Novavax cut to neutral at JP Morgan; manufacturing issues citedNovavax (NVAX) topped Street estimates with its Q1 2021 financials, but a delayed timeline outlined for its COVID-19 vaccine candidate hurt the stock yesterday leading to a ~14.4% slump.Today, J.P. Morgan has downgraded ...
Image source: The Motley Fool. Halozyme Therapeutics Inc (NASDAQ: HALO) Q1 2021 Earnings Call May 10, 2021 , 4:30 p.m. ET Operator Continue reading For further details see: Halozyme Therapeutics Inc (HALO) Q1 2021 Earnings Call Transcript...
Halozyme Reports First Quarter 2021 Results - First Quarter Revenue of $89.0 million, Up from $25.4 million in First Quarter of 2020 - - Record Quarterly Royalties in the First Quarter of $36.9 million Representing 119% Growth over First Quarter 2020 - - Reiterate 2021 R...
[[ACM]], [[AEE]], [[AFRM]], [[BHF]], [[BRKS]], [[CNNE]], [[CPSI]], [[CSTL]], [[DDD]], [[EGHT]], [[ELY]], [[EVBG]], [[FGEN]], [[FOE]], [[G]], [[HALO]], [[HHC]], [[HLIO]], [[IFF]], [[INO]], [[IPAR]], [[JCOM]], [[MBI]], [[MESA]], [[MGNI]], [[MODN]], [[MRVI]], [[NCMI]], [[NHI]], [[NLOK]], [[NLS]]...
Halozyme Therapeutics (NASDAQ:HALO) is scheduled to announce Q1 earnings results on Monday, May 10th, after market close.The consensus EPS Estimate is $0.32 and the consensus Revenue Estimate is $84.88M.Over the last 2 years, HALO has beaten EPS estimates 50% of the time and has beaten r...
Halozyme to Present at BofA Securities 2021 Virtual Health Care Conference PR Newswire SAN DIEGO , April 29, 2021 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced that Dr. Helen Torley , president and chief executive officer, wi...
Halozyme To Host First Quarter 2021 Financial Results Webcast And Conference Call PR Newswire SAN DIEGO , April 20, 2021 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) will webcast its Quarterly Update Conference Call for the first quarte...
As the patron saint of value investors, Warren Buffett's strategies for picking stocks -- and his preferences for holding them for the long term -- are so well-known that they're practically cliches. But don't let your familiarity with his approach trick you into thinking that it's stale. B...
News, Short Squeeze, Breakout and More Instantly...
Halozyme Therapeutics Inc. Company Name:
HALO Stock Symbol:
NASDAQ Market:
Halozyme Therapeutics Inc. Website:
Halozyme to Report Second Quarter 2024 Financial and Operating Results PR Newswire SAN DIEGO , July 23, 2024 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced it will release its second quarter 2024 financial and operating re...
2024-07-22 03:26:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...